Literature DB >> 35309640

An epidemic of iatrogenic Cushing's syndrome in anticipation in post-COVID era.

Subhankar Chatterjee1, Ritwik Ghosh2, Bhagya Vardhan1, Umesh Kumar Ojha1, Sanjay Kalra3.   

Abstract

Entities:  

Year:  2022        PMID: 35309640      PMCID: PMC8930165          DOI: 10.4103/jfmpc.jfmpc_1523_21

Source DB:  PubMed          Journal:  J Family Med Prim Care        ISSN: 2249-4863


× No keyword cloud information.
Dear Editor, Rampant use of steroids resulting in uncontrolled hyperglycemia and immunosuppression is the key reason behind the upsurge of diabetes and epidemic of mucormycosis in the second wave of coronavirus disease-2019 (COVID-19) in India.[12] Now, we should be aware of the upcoming next storm, that is, post-COVID iatrogenic Cushing's syndrome (PICS). Even at the end of first wave of COVID-19, efficacy and safety of using glucocorticoids were not established.[34] Current guidelines recommend steroids in hypoxic COVID-19 patients to decrease severity and mortality.[5] The World Health Organization recommends dexamethasone up to 6 mg/day (or equivalent dosage of prednisone, methylprednisolone, hydrocortisone) for 5–10 days for hypoxic COVID-19 patients.[5] A study reveals that there is considerable variation in steroid dose, form, initiation, and stopping criteria among physicians.[6] Contrary to the existing recommendations, majority of them prefer high-dose methylprednisolone therapy and continue the same beyond 2 weeks. Prescriptions of methylprednisolone 1 g or dexamethasone 24 mg daily are being advised. In many instances, patients are being put on very high dose of intravenous steroid even more than 2 weeks till they get discharged, and further oral steroids prescribed at discharge are being continued for a prolonged period (sometimes over a month).[67] Inhalational corticosteroids, approved this year for mild COVID-19 cases, can also lead to PICS, if used unrestricted.[8] Although still not reported in the context of COVID-19, posaconazole, a drug approved for mucormycosis, can itself cause Cushing's syndrome.[9] Tele-COVID care often fails to determine the exact time and clinical status when steroid should be initiated or stopped, leading to its unregulated use. While corticosteroids have emerged as the holy grails in the management of COVID-19, over-the-counter (OTC) misuse of steroids by lay public is a matter of concern. Unregulated, unrestricted application of steroids by quacks and alternative medical practitioners during this pandemic will likely make the scenario even worse.[1011] A handful of herbal medicines against COVID-19 being used by indigenous practitioners contain steroids[1112] and their misuse will further complicate the scenario. To curb PICS, loopholes in existing guidelines should be sealed. There should be clear recommendations regarding maximum approved dosage and duration of steroid use in COVID-19.[67] To avoid prolonged ingestion of oral steroid after discharge, consensus guidelines must be released on how steroid dose is to be tapered off.[6] Prescription audit by authorities is the need of the hour. OTC sale of steroids should be banned. Being an immunosuppressive state, PICS will lead to diminished antibody response and vaccination failure. Moreover, associated hyperglycemia and immunosuppression create a perfect milieu for repeated COVID-19 infection.[3] Physicians should be aware of the possible upsurge of PICS in times to come and should suspect it even on subtle clinical or biochemical clues. Equal vigilance is needed to detect impending Addison's crisis.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  10 in total

Review 1.  COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

Authors:  Dâmaris Silveira; Jose Maria Prieto-Garcia; Fabio Boylan; Omar Estrada; Yris Maria Fonseca-Bazzo; Claudia Masrouah Jamal; Pérola Oliveira Magalhães; Edson Oliveira Pereira; Michal Tomczyk; Michael Heinrich
Journal:  Front Pharmacol       Date:  2020-09-23       Impact factor: 5.810

2.  Practice Pattern of Critical Care Physicians in India for Use of Corticosteroids in COVID-19.

Authors:  Deven Juneja; Ravi Jain; Omender Singh
Journal:  J Assoc Physicians India       Date:  2021-05

3.  Iatrogenic Cushing's syndrome induced by posaconazole.

Authors:  Benoit Pilmis; Hélène Coignard-Biehler; Vincent Jullien; Olivier Hermine; Philippe Touraine; Marc Lecuit; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

Review 4.  COVID-19: the endocrine opportunity in a pandemic.

Authors:  Subhankar Chatterjee; Ritwik Ghosh; Payel Biswas; Souvik Dubey; Rishi T Guria; Chandra B Sharma; Sanjay Kalra
Journal:  Minerva Endocrinol       Date:  2020-06-16       Impact factor: 2.184

5.  Resurgence of COVID-19 and diabetes in India.

Authors:  Rimesh Pal; Sanjay K Bhadada; Anoop Misra
Journal:  Diabetes Metab Syndr       Date:  2021-05-07

6.  Inhalational Steroids and Iatrogenic Cushing's Syndrome.

Authors:  Raveendran A V
Journal:  Open Respir Med J       Date:  2014-01-31

7.  On the use of corticosteroids for 2019-nCoV pneumonia.

Authors:  Lianhan Shang; Jianping Zhao; Yi Hu; Ronghui Du; Bin Cao
Journal:  Lancet       Date:  2020-02-12       Impact factor: 79.321

8.  Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.

Authors:  Awadhesh Kumar Singh; Ritu Singh; Shashank R Joshi; Anoop Misra
Journal:  Diabetes Metab Syndr       Date:  2021-05-21

9.  A living WHO guideline on drugs for covid-19

Authors:  Arnav Agarwal; Bram Rochwerg; François Lamontagne; Reed Ac Siemieniuk; Thomas Agoritsas; Lisa Askie; Lyubov Lytvyn; Yee-Sin Leo; Helen Macdonald; Linan Zeng; Wagdy Amin; André Ricardo Araujo da Silva; Diptesh Aryal; Fabian AJ Barragan; Frederique Jacquerioz Bausch; Erlina Burhan; Carolyn S Calfee; Maurizio Cecconi; Binila Chacko; Duncan Chanda; Vu Quoc Dat; An De Sutter; Bin Du; Stephen Freedman; Heike Geduld; Patrick Gee; Matthias Gotte; Nerina Harley; Madiha Hashimi; Beverly Hunt; Fyezah Jehan; Sushil K Kabra; Seema Kanda; Yae-Jean Kim; Niranjan Kissoon; Sanjeev Krishna; Krutika Kuppalli; Arthur Kwizera; Marta Lado Castro-Rial; Thiago Lisboa; Rakesh Lodha; Imelda Mahaka; Hela Manai; Marc Mendelson; Giovanni Battista Migliori; Greta Mino; Emmanuel Nsutebu; Jacobus Preller; Natalia Pshenichnaya; Nida Qadir; Pryanka Relan; Saniya Sabzwari; Rohit Sarin; Manu Shankar-Hari; Michael Sharland; Yinzhong Shen; Shalini Sri Ranganathan; Joao P Souza; Miriam Stegemann; Ronald Swanstrom; Sebastian Ugarte; Tim Uyeki; Sridhar Venkatapuram; Dubula Vuyiseka; Ananda Wijewickrama; Lien Tran; Dena Zeraatkar; Jessica J Bartoszko; Long Ge; Romina Brignardello-Petersen; Andrew Owen; Gordon Guyatt; Janet Diaz; Leticia Kawano-Dourado; Michael Jacobs; Per Olav Vandvik
Journal:  BMJ       Date:  2020-09-04

10.  Corticosteroids for COVID-19: the search for an optimum duration of therapy.

Authors:  Gyanshankar P Mishra; Jasmin Mulani
Journal:  Lancet Respir Med       Date:  2020-11-26       Impact factor: 30.700

  10 in total
  1 in total

1.  Glucocorticoid Use Audits.

Authors:  Jubbin Jagan Jacob; Sanjay Kalra
Journal:  Indian J Endocrinol Metab       Date:  2022-08-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.